In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

A new alert from the FDA warns that some sensors from Abbott may give incorrect blood sugar readings, which could lead to unsafe treatment decisions.

Global healthcare giant Abbott is recalling faulty blood glucose sensors across multiple countries due to potentially ...

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, ...

Some FreeStyle Libre 3 glucose sensors made by Abbott Diabetes Care may give incorrect low readings. The devices have been linked to potential deaths.

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

Worldwide Revenue: $1.21 billion, up 22% year-over-year. US Revenue: $852 million, a 21% increase from the previous year. International Revenue: $357.4 million, with an 18% organic growth rate. Gross ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...